Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing ...
Corcept Therapeutics Incorporated is a Strong Buy after early FDA approval of Lyforli for PROC, with upside from EU decisions ...
Organ transplantation remains the cornerstone treatment for end-stage organ failure. While conventional broad-spectrum immunosuppression effectively controls acute rejection, it fails to address ...
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, ...
Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment ...
PowerHome is a manufacturer and global supplier of power conversion equipment, specializing in single-phase and three-phase ...
Drug Farm today announced ophthalmologic and central nervous system (CNS) findings from its Phase 1b study of DF-003, a first ...
Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, ...
Experts are already treating addicted people with at-home neuromodulation devices to control cravings, and the future is ...
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
A new technical paper, “Nonvolatile photonic field-programmable coupler array,” was published by researchers at University of ...
Detailed price information for Maplight Therapeutics Inc (MPLT-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results